- Home » News and EventsPage 10
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent to Supply Edenbridge Pharmaceuticals with a Patient-Focused Fast-Dissolve Zydis® Formulation of Glycopyrrolate Intended for Use as Adjunctive Therapy in the Treatment of Patients with Peptic Ulcer
Aug 10, 2021
Catalent has signed a commercial supply agreement with Edenbridge Pharmaceuticals, for a novel formulation of glycopyrrolate using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) delivery technology intended for use as adjunctive therapy in the treatment of patients with peptic ulcer.
Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Based Target Initiative to Reduce Carbon Footprint
Aug 3, 2021
Catalent announced that, effective July 1, 2021, 97% of its electricity usage across its global network is being procured from renewable energy sources such as wind, solar, hydroelectric, and biomass.
DisperSol and Catalent Collaborate to Establish KinetiSol® Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline
Aug 2, 2021
DisperSol Technologies and Catalent today announced a strategic manufacturing collaboration to accelerate the development of multiple DisperSol pharmaceutical products.
Catalent Launches New OptiDose® Design Solution to Help Create Differentiated Treatments that are Successful for Innovators, Patients and Health Care Professionals
Jul 26, 2021
Catalent today announced the launch of its new OptiDose® Design Solution, a comprehensive assessment of your molecule, patient, and market, to help drive the dose design decision-making process and create successful treatments.
Catalent Biologics Launches New GPEx® Lightning Cell Line Expression Technology to Shorten Drug Substance Development Timelines by up to Three Months
Jul 22, 2021
Leveraging Catalent’s proven GPEx® expression platform in a glutamine synthase (GS) knock-out Chinese hamster ovary (CHO) cell line system, GPEx Lightning combines innovative technologies to further shorten drug substance development timelines.
Catalent Plans Multi-Phase, $100 Million Expansion of Italian Facility to Increase Biologics Manufacturing Capabilities in Europe
Jul 21, 2021
Catalent today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.
Catalent Signs Agreement with JOS Pharmaceuticals to Develop Fast-Dissolve Zydis® Formulation for Cannabidiol as an Anesthesia Premedication
Jul 13, 2021
Catalent has signed a development agreement with JOS Pharmaceuticals. Under the agreement, Catalent will undertake a feasibility study for the potential development of a licensed cannabidiol (CBD) product for use as an anesthetic premedication using Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology.
Catalent Receives RoSPA Gold Award for Health and Safety Practices
Jun 28, 2021
Catalent today announced that it has been recognized by the Royal Society for the Prevention of Accidents (RoSPA) for demonstrating high health and safety standards.
Catalent to Acquire RheinCell Therapeutics, Strengthening a Path Towards Industrialization of Induced Pluripotent Stem Cell-based Therapies
Jun 24, 2021
Catalent today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs).
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.